

30 May 2025

Site activation for innovative clinical trial at West Los Angeles VA Medical Center

Highlights:

- **Innovative clinical trial to screen for a current major depressive episode (cMDE) in veterans to commence at the West Los Angeles VA Medical Center**
- **Equipment procurement and training of on-site physicians completed with patient recruitment to commence shortly**
- **Up to 30 trial participants with suspected sleep apnea to be recruited from the West Los Angeles VA Medical Center – part of the Greater Los Angeles VA Healthcare System**
- **The trial is expected to take approximately 12 weeks from commencement**

Perth, Australia, and Minneapolis, USA: TrivarX Limited (‘the Company’) (ASX: TRI) is pleased to confirm that site activation has been completed for its single-channel ECG algorithm trial in veterans, being undertaken with the Greater Los Angeles Veterans Research and Education Foundation (GLAVREF) and the Veterans Affairs (‘VA’) Greater Los Angeles Healthcare System (refer ASX announcement: 13 March 2025).

Equipment procurement and training of on-site clinicians is now complete, following Institutional Review Board (IRB) approval for the clinical trial protocol (refer ASX announcement: 28 April 2025) which facilitated the formal commencement of the trial.

The trial is being conducted at the West Los Angeles VA Medical Center – the primary VA facility in the greater Los Angeles area – and is expected to take approximately 12 weeks from commencement. With site activation now complete, the patient enrolment process will commence with up to 30 trial participants with suspected sleep apnoea to be enrolled.

The trial has been designed to assess the sleep scoring and cMDE screening accuracy of TrivarX’s single-channel ECG algorithm, which is an extension of its lead asset, MEB-001. The algorithm accurately conducts sleep staging and screens for cMDE in subjects using heart rate (HR) and heart rate variability (HRV) metrics.

Results from the Company’s Phase 2 trial on 195 patients demonstrated a sensitivity of 87% (95% CI 74-95%) and specificity of 67% (95% CI 62-73%) for identifying cMDE. The potential application of TrivarX’s innovative single-channel algorithm has the potential to unlock major commercialization opportunities for expanded use of TRI’s technology.

Commentary:

Non-executive Chairman, David Trimboli said: *“We are pleased to confirm that site activation is complete, ahead of the pending recruitment of patients. Preparations for the trial – including the requisite training of physicians and equipment procurement – have been completed in close cooperation with our research partners, GLAVREF and the Veterans Affairs Greater Los Angeles Healthcare System. We look forward to providing further updates this month as patient enrolment gets underway.”*

ASX ANNOUNCEMENT



This announcement is authorised for release by the Board of Directors of TrivarX Limited.

ENDS

Investor Enquiries:

Henry Jordan – Six Degrees Investor Relations

Henry.jordan@sdir.com.au

+61 431 271 538

About TrivarX Limited:

TrivarX (ASX: TRI) (OTCPINK: MDBIF) is a mental health technology company pioneering the use of objective measures to aid in the early detection and screening of mental health conditions. The Company was founded in Australia, with offices located in Perth (WA) and Minneapolis (MN, USA). TrivarX is listed on the Australian Securities Exchange Ltd and trades on the OTCQB Venture Market. Investors can find additional information on www.otcmarkets.com and www.asx.com.au

For personal use only